

Q1 2023 Results

The TELEMEDICINE TECHNOLOGIES Group has started the fiscal year with a new expansion of its activities in the Clinical Research software market and is structuring its recent acquisitions.

- The Group declares for Q1 a growth in billings of nearly 20% in the Clinical Research market, In line with the good performance recorded in 2022

| As of 2023/03/31 k€ | Q1 2022 | Q1 2023 | % Growth |
|--------------------------|---------|---------|----------|
| France | 545 | 651 | +19,5 % |
| Belgique (Data Services) | 113 | 128 | +13,3 % |
| TOTAL | 658 | 779 | +18,4 % |

The growth observed in Q1 is a direct result of the investments made in 2022, namely the recruitments made to maintain a sustained pace of enhancement of the Cleanweb solution, to develop a Data platform and to set up an e-learning platform.

- During Q1 2023, the Group continued the integration of the two companies acquired in 2022 (CTMA and Dapsys), and initiated their restructuring to take advantage of their assets

During Q1, the Group has positioned itself in markets directly complementary to its historical market, the Sponsor market:

- Complementing CTMA's Patient Recruitment assistance solutions, launch of an investment program to move into the Investigator Center market, a market that is being organized with the increase in decentralized clinical trials.
- Promotion of the appointment booking engine of the VisionHM solution from Dapsys, for the Clinical Research pathways.
- Web migration of the VisionHM solution.
- At the end of Q1 2023, the Group had secured 53% of its 2023 revenue target and confirmed its objectives

| Au 31/03/2023 k€ | Clinical Research | Patient Pathway | TT Group |
|--------------------------------|-------------------|-----------------|----------|
| Q1 Revenues + Backlog 2023 (1) | 2.006 | 394 | 2.400 |
| 2023 Revenue target 2023 | 3.995 | 632 | 4.567 |
| % Achieved end of Q1 | 51% | 62% | 53% |

(1) Backlog 2023 = amount as of March 31, 2023 of projects in progress, contracted and still to be invoiced in 2023

- **Upcoming events**

- General Meeting: April 25, 2023 (Capital increase following the acquisition of CTMA, decision to merge CTMA SAS and DAPSYS SARL into the parent company TELEMEDICINE TECHNOLOGIES SAS)
- Annual General Meeting: May 31, 2023 (Approval of the accounts of the parent company TELEMEDICINE TECHNOLOGIES SAS)
- 2nd quarter 2023 revenues : July 12, 2023
- Half-year results 2023: July 20, 2023